CytoSorbents Corporation (CTSO)

[Makenlight]

Evaluation of an experimental filter designed for improving the quality of red blood cells (RBCs) during storage.

“Slide 39: … And as you can see, there are companies like Haemonetics that cross over from blood transfusion to cardiac surgery. Maquet crosses over from cardiac surgery to critical care. Companies like Fresenius are on the dialysis side as well as on the blood transfusion side. You can see how CytoSorbents’ technology could be very synergistic to the larger businesses of companies like these, as an example. We address so many major markets that have billion dollar revenue potential that if we are successful, we can impact the top and bottom line growth of most major multi-national corporations, which is something that you cannot normally say of technologies from small companies such as ours.”

That being said…

Transfusion. 2014 Mar;54(3):592-601. doi: 10.1111/trf.12330. Epub 2013 Jul 9.
Evaluation of an experimental filter designed for improving the quality of red blood cells (RBCs) during storage by simultaneously removing white blood cells and immunomodulators and improving RBC viscoelasticity and Band 3 proteins.
Sowemimo-Coker SO.
Author information Haemonetics Corporation, Braintree, Massachusetts.
Abstract
BACKGROUND: Storage age of red blood cells (RBCs) has been reported to be associated with increased mortality and morbidity. During storage, RBCs undergo changes in biochemical and functional properties. Stored RBCs may also contain white blood cells (WBCs), activated platelets (PLTs), cytokines, immunoglobulin, and other bioactive proteins. Transfusion of these bioactive proteins and cells with RBCs has the potential to cause serious adverse effects. We evaluated the performances of an experimental filter (EF) designed to remove immunoglobulins, cytokines, and other bioactive proteins in RBCs.
STUDY DESIGN AND METHODS: Sixteen sets, each containing 3 units of ABO-identical RBCs in AS-3 were obtained from a blood bank. Three units of RBCs were combined together and then split into three equal aliquots, A, B, and C. Unit A was unfiltered while Units B and C were filtered with a leukoreduction filter and the EF, respectively. All the units were stored at 4°C in a blood bank refrigerator for 42 days. We measured RBC viscoelasticity, hemolysis, RBC adenosine triphosphate, Band 3 proteins, cytokines, PLTs, WBCs, and immunoglobulin before and after filtration and on Days 21 and 42 of storage. Data were analyzed by repeated-measures analysis of variance with Newman-Keuls multiple comparison test.
RESULTS: The EF significantly (p<0.05) reduced the levels of immunoglobulin (control IgG, 2.184 ± 1.918 mg/mL; BPF4, 2.216 ± 1.956 mg/mL; and EF, 0.363 ± 0.391 mg/mL), PLTs, cytokines, and improved viscoelastic properties when compared to either control or leukoreduced RBCs.

CONCLUSION: The EF achieved lower levels of WBCs, improved viscoelastic properties, and reduced levels of immunoglobulins and cytokines but significance will require clinical evaluation.


http://www.ncbi.nlm.nih.gov/pubmed/23834280